Abstract
The main outcomes of the Programa Español para Tratamiento de Hemopatías (PETHEMA)-acute lymphoblastic leukaemia (ALL)-Ph-08 trial were described and compared with those of the historical PETHEMA-CSTIBES02 trial. The trials differed in imatinib dose (600 vs. 400 mg/d) and amount of chemotherapy (one vs. two consolidation cycles) before stem cell transplantation (SCT). All patients (n = 29) enrolled in the ALL-Ph-08 trial achieved complete remission (CR) (vs. 90% in CSTIBES02), and SCT was performed in CR in 90% (vs. 78%). The reduction in early death, relapse before SCT and transplant-related mortality observed in the ALL-Ph-08 trial resulted in an improved 2-year event-free survival (63% vs. 37%, P = 0·009).
© 2012 Blackwell Publishing Ltd.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Benzamides
-
Combined Modality Therapy
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Dexamethasone / administration & dosage
-
Disease-Free Survival
-
Etoposide / administration & dosage
-
Female
-
Humans
-
Imatinib Mesylate
-
Male
-
Mercaptopurine / administration & dosage
-
Methotrexate / administration & dosage
-
Middle Aged
-
Piperazines / administration & dosage*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery*
-
Prednisone / administration & dosage
-
Pyrimidines / administration & dosage*
-
Stem Cell Transplantation / methods*
-
Transplantation, Homologous
-
Treatment Outcome
-
Vincristine / administration & dosage
-
Young Adult
Substances
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Cytarabine
-
Vincristine
-
Etoposide
-
Dexamethasone
-
Imatinib Mesylate
-
Mercaptopurine
-
Prednisone
-
Methotrexate
-
Daunorubicin